Navigation Links
Marinus Pharmaceuticals Announces U.S. Department of Defense Grant to Study Ganaxolone in Fragile-X Syndrome
Date:4/13/2011

NEW HAVEN, Conn., April 13, 2011 /PRNewswire/ -- Marinus Pharmaceuticals, Inc., the leader in the development of neurosteroids for central nervous system disorders, today announced the award of a $3 million grant by the U.S. Department of Defense to study its lead candidate ganaxolone for the treatment of Fragile-X Syndrome (FXS). Ganaxolone modulates GABA-A ion channels by selective binding to the neurosteroid receptor. Early research suggests that normalizing neurosteroid levels with ganaxolone treatment may eliminate the behavioral symptoms associated with FXS.

The $3 million federal grant was awarded to three University of California, Davis (UCD) researchers: Randi Hagerman, M.D., an international authority on Fragile X-related disorders; Michael Rogawski, M.D., Ph.D., a world-renowned epilepsy researcher; and David Hessl, Ph.D., an expert in psychophysiology studies. The group will enroll 60 children between the ages of six and 17 years to study the safety and effectiveness of ganaxolone for treating behaviors and anxiety common with FXS.

"The fact that a study with ganaxolone was awarded this grant is a testament to the potential for neurosteroid augmentation as a new treatment for FXS patients," stated Gail Farfel, Ph.D., Chief Clinicaland Regulatory Officer of Marinus. "The scientific data suggests that ganaxolone may be ideally suited to reverse FXS symptoms related to the down-regulation of the neurosteroid binding site on GABA-A ion channels."

"Over the next few months, we will work with UCD to provide ganaxolone for the FXS study and work on obtaining regulatory approval from the Food and Drug Administration to allow the researchers to conduct this study under Marinus' Investigational New Drug Application," commented Kenneth Shaw, Ph.D., Senior Vice President, R&D at Marinus.

About Ganaxolone

Ganaxolone is a synthetic neurosteroid and a derivative of the naturally occurring neuromodulator, allopregnanolon
'/>"/>

SOURCE Marinus Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Marinus Pharmaceuticals Issued Patent for Ganaxolone
2. Conatus Pharmaceuticals Completes the Second Closing of its Series B Private Placement Financing
3. MAP Pharmaceuticals to Present Data From LEVADEX® Pharmacokinetics and Pharmacodynamics Safety Studies at the 63rd Annual Meeting of the American Academy of Neurology
4. Avanir Pharmaceuticals Announces Appointment of William Sibold as Chief Commercial Officer
5. Valeant Pharmaceuticals Files Presentation for Cephalon Stockholders
6. Webcast and Conference Call Alert: Isis Pharmaceuticals Holds Webcast to Discuss Recent Advances in its Development Pipeline
7. Auxilium Pharmaceuticals, Inc. Announces Launch of XIAPEX® in EU by Pfizer
8. Vanda Pharmaceuticals Announces Commencement of Clinical Study of Long-Acting Injectable Formulation of Fanapt®
9. Idenix Pharmaceuticals Prices Public Offering of Common Stock
10. Pacira Pharmaceuticals to Present at BioCentury Future Leaders in the Biotech Industry Conference
11. Idenix Pharmaceuticals Announces Proposed Public Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)...  In an effort to raise awareness and the ... DentaQuest established the Health Equity Hero Awards to celebrate ... More than 83 million people in ... care. These barriers are most significant for those who ... language, health literacy or geographic isolation.   "Connecting ...
(Date:5/4/2015)... -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) today announced ... company as Vice President, Medical Affairs. ... Aurora to the Neurocrine team as our Vice ... and Chief Executive Officer of Neurocrine Biosciences. "Bill,s experience ... with his extensive network and influence with psychiatric and ...
(Date:5/4/2015)... 2015 Microbrush International, a leading developer, producer ... restorative procedures, today announced the acquisition of DentiSmart ... sectional matrix system used in dental restorative procedures. ... opportunity to add DentiSmart to our growing portfolio ... VP and General Manager of Microbrush. "DentiSmart,s products ...
Breaking Medicine Technology:DentaQuest Honors Seven Oral Health Leaders As Health Equity Heroes With Inaugural National Award 2DentaQuest Honors Seven Oral Health Leaders As Health Equity Heroes With Inaugural National Award 3DentaQuest Honors Seven Oral Health Leaders As Health Equity Heroes With Inaugural National Award 4Neurocrine Biosciences, Inc. Announces Appointment of Dr. Bill Aurora as Vice President, Medical Affairs 2Neurocrine Biosciences, Inc. Announces Appointment of Dr. Bill Aurora as Vice President, Medical Affairs 3Microbrush International Announces Acquisition of DentiSmart 2
... NeoStem, Inc. (NYSE Amex: NBS ) ("NeoStem" ... the U.S. and China, commented today on the ruling this ... from funding research involving human embryonic stem cells.  In issuing ... first passed in 1996 prohibiting federal money for research where ...
... KemPharm, Inc. announced today that it has received a ... Trademark Office (USPTO) for its patent application entitled "Non-Standard ... and Using the Same", U.S. Patent No. 7,776,917 B2. ... No. 7,772,222, provides broad protection of the Company,s Ligand ...
Cached Medicine Technology:NeoStem Comments on Recent Court Ruling Blocking the Federal Government's Funding of Embryonic Stem Cell Research 2NeoStem Comments on Recent Court Ruling Blocking the Federal Government's Funding of Embryonic Stem Cell Research 3KemPharm, Inc. Receives Notice of Issuance from USPTO on Second Patent Protecting Company's ADHD Prodrug Technology 2KemPharm, Inc. Receives Notice of Issuance from USPTO on Second Patent Protecting Company's ADHD Prodrug Technology 3
(Date:5/4/2015)... Jersey (PRWEB) May 04, 2015 Parlin dentist, ... give a chance to more youths to participate and win ... youths in her area to do good deeds and share ... intends to empower their minds and teach them to be ... is accessible to any youth 18 years of age and ...
(Date:5/4/2015)... May 05, 2015 The National ... Hommes as a 2015-2016 inductee into its VIP ... this prestigious distinction for leadership in business. NAPW is ... boasting more than 700,000 members and over 200 operating ... this important honor,” says NAPW President Star Jones. “Her ...
(Date:5/4/2015)... 05, 2015 The National Association ... as a 2015-2016 inductee into its VIP Woman ... prestigious distinction for leadership in healthcare. NAPW is the ... more than 700,000 members and over 200 operating Local ... important honor,” says NAPW President Star Jones. “Her perseverance, ...
(Date:5/4/2015)... 2015 Global Vision, the industry ... today announced that it will showcase Proofware at ... Center, in Nashville Tennessee, May 04 and May ... true all-in-one we-based packaging inspection suite, giving enterprise-wide ... of their brand copy and artwork. Proofware offers ...
(Date:5/4/2015)... Hollywood, California (PRWEB) May 04, 2015 ... of holistic treatment for substance absue, Per Wickstrom, the ... Durkin Entertainment’s EcoLuxe Lounge and the “Salute to the ... the Stardust Penthouse on the top floor of the ... Durkin, Los Angeles’ top producer of sustainable product placement ...
Breaking Medicine News(10 mins):Health News:10 More Days To Enter Good Deed Contest 2Health News:NAPW Inducts Patti Hommes, Director of Advancement Services, Springside Chestnut Hill Academy, a 2015-2016 Professional Woman of the Year Circle 2Health News:National Association of Professional Women Inducts Shirley Weis, President at Weis Associates, LLC, into its 2015-2016 VIP Woman of the Year Circle 2Health News:National Association of Professional Women Inducts Shirley Weis, President at Weis Associates, LLC, into its 2015-2016 VIP Woman of the Year Circle 3Health News:Global Vision to Spotlight Proofware at INFO*FLEX 2015 2Health News:Per Wickstrom Interviews TV and Film Star Carolyn Hennesy About Substance Abuse and Treatment 2
... health benefits of anti-oxidants, more specifically Vitamin E has ... ,Everyday, a number of studies are studies are being ... has warned that under certain circumstances, the even the ... development of cardiovascular disease, cancer and other disorders. ...
... New South Wales have discovered that temporary injury ... fever// could lead to chronic fatigue syndrome (CFS). ... regions of the brain that play a critical role ... glandular fever infection could damage the above-mentioned regions of ...
... regarding an appeal by health officials, requesting the withdrawal of ... Lawyers who are currently handling the case of this severely ... poor and that doctors should be allowed to let him ... treating physicians have not been revealed due to controversies surrounding ...
... Avastin, a cancer drug may cause trigger a rare ... in the New England Journal of Medicine. ... their 50s treated with Avastin developed reversible posterior leukoencephalopathy ... complications. Doctors said that both the patients have recovered. ...
... to the study it was found that GlaxoSmithKline Plc ... against middle-ear infections in infants// said that the vaccine ... maker. ,Roman Prymula, who led the study ... further tests are necessary before the vaccine hits the ...
... comes the news that a stroll followed by a glass of ... individual.// ,This is in the direction of efforts by the ... non-pharmaceutical means to maintain muscle function and quality of life in ... to make athletes out of the elderly, but to increase our ...
Cached Medicine News:Health News:Vitamin E Can Lead To Heart Disease And Cancer 2Health News:Brain Injury, A Consequence Of Glandular Fever Could Trigger Fatigue Syndrome 2Health News:Life Or Death: Parents Await High Court Judgment 2
Solid 14 mm blades. Dull finish....
Angled upward 45 degrees for temporal approach. Open 14 mm blades....
Pediatric model. Blades: 10 mm. Solid blades with locking mechanism. Dull finish....
Speculum with malleable plate to support flap during ablation of thestromal bed....
Medicine Products: